LENZ Therapeutics, Inc. (LENZ) Stock Price, Financials & Summary

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16Sep 21

Key dataSep 21, 2026

Open$4.12

From 52W high−91.68%

Volume21338.00

Market cap$128.19M

P/E (TTM)—

P/S (TTM)6.0x

Div yield—

Key dataSep 21, 2026

Open

$4.12

From 52W high

−91.68%

Volume

21338.00

Market cap

$128.19M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.7x

P/E (TTM)

—

RSI (14)

32.7

MomentumView details →

1D Return

+0.25%

YTD Return

−74.47%

SummaryUpdated Jun 1, 2026

LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for presbyopia, a common age-related vision condition. The company went public in March 2024 and is headquartered in Del Mar, California. LENZ is currently preparing for the potential commercial launch of its lead product candidate LNZ100, which has completed Phase III clinical trials and has a pending New Drug Application (NDA) with the FDA, with a target approval date of August 8, 2025.

Ask drillr about LENZ Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.7x

EV/Sales

−4.3x

P/S (TTM)

6.0x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

90.14%

Net Margin

−586.74%

EBITDA Margin

−584.61%

ROE (TTM)

−57.47%

ROA (TTM)

−53.26%

Asset Turnover

0.08x

GrowthView details →

Revenue YoY

+329.50%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+8.37%

EPS CAGR 3Y

−21.79%

EBITDA YoY

—

MomentumView details →

1D Return

+0.25%

YTD Return

−74.47%

1Y Return

−90.34%

RSI (14)

32.7

vs 50D SMA

−19.06%

vs 200D SMA

−60.67%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.55x

Quick Ratio

13.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.02

EPS Surprise

2.86%

Beats (12Q)

5/12

Next Q EPS Est

−$0.93

Avg Surprise (4Q)

−8.17%

Rev Surprise

130.76%

Financials snapshotView financials →

Revenue (TTM)

21.48M

Net Income (TTM)

−126.00M

Op. CF (TTM)

−113.91M

Next earningsNov 4, 2026 →

Latest newsMore news →

LENZ Therapeutics reported its second quarter 2026 financial results, with total revenue of $5.5 million from VIZZ product sales and global license agreements.41d ago

LENZ Therapeutics launched a new telehealth prescribing option for VIZZ to treat presbyopia.77d ago

Similar companies

enGene Holdings Inc.ENGN Inovio Pharmaceuticals, Inc.INO Cibus, Inc.CBUS vTv Therapeutics Inc.VTVT Biomea Fusion, Inc.BMEA Insight Molecular Diagnostics Inc.IMDX Find similar companies →

Latest newsMore news →

LENZ Therapeutics reported its second quarter 2026 financial results, with total revenue of $5.5 million from VIZZ product sales and global license agreements.41d ago LENZ Therapeutics launched a new telehealth prescribing option for VIZZ to treat presbyopia.77d ago LENZ Therapeutics and Arrotex Pharmaceuticals entered into an exclusive license and commercialization agreement for VIZZ in Australia and New Zealand.89d ago